Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today

Open Access 28-03-2024 | Kidney Transplantation | Original Article

Lung cancer after kidney transplantation: a 50-year experience at a single institution

Authors: Hiroki Watanabe, Yuka Kadomatsu, Shuhei Hakiri, Hiromu Yoshioka, Takahisa Hiramitsu, Kenta Futamura, Manabu Okada, Norihiko Goto, Shunji Narumi, Yoshihiko Watarai, Toyofumi Fengshi Chen-Yoshikawa

Published in: Surgery Today

Login to get access

Abstract

Purpose

To investigate the clinical characteristics of lung cancer that develops after kidney transplantation.

Methods

The clinical data of patients with lung cancer diagnosed after kidney transplantation were collected retrospectively. The medical records were extracted from our database. All patients underwent routine chest examination after kidney transplantation.

Results

In total, 17 lung tumors were detected in 15 (0.6%) of 2593 patients who underwent kidney transplantation at our institution. Eleven lung tumors were completely resected from a collective 10 patients (surgical group). The remaining five patients did not receive surgical treatment (nonsurgical group). The surgical group underwent wedge resection (n = 5), segmentectomy (n = 1), lobectomy (n = 3), and bilobectomy (n = 1). The pathological stages were 0 (n = 1), IA1 (n = 2), IA2 (n = 4), IA3 (n = 2), and IB (n = 1). The surgical group had a significantly better prognosis than the nonsurgical group. There were no perioperative complications related to kidney transplantation in either group.

Conclusions

Routine chest examination would be useful for the early diagnosis and treatment of lung cancer after kidney transplantation. Moreover, surgical resection for early-stage lung cancer was associated with a better prognosis for kidney transplantation patients.
Literature
1.
Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6:511–9.CrossRefPubMed
2.
Chen-Yoshikawa TF, Fukui T, Nakamura S, Ito T, Kadomatsu Y, Tsubouchi H, et al. Current trends in thoracic surgery. Nagoya J Med Sci. 2020;82:161–74.PubMedPubMedCentral
3.
Chen-Yoshikawa TF, Date H. Three-dimensional image in lung transplantation. Gen Thorac Cardiovasc Surg. 2018;66:19–26.CrossRefPubMed
4.
Watarai Y, Danguilan R, Casasola C, Chang SS, Ruangkanchanasetr P, Kee T, et al. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study. Clin Transplant. 2021;35: e14415.CrossRefPubMedPubMedCentral
5.
Hidaka Y, Goto N, Yamanaga S, Kinoshita K, Tanaka K, Kawabata C, et al. Two-year outcomes of low-exposure extended-release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multi-center randomized controlled trial. Clin Transplant. 2022;36: e14655.CrossRefPubMed
6.
Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, et al. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: retrospective single center assessment. Int Immunopharmacol. 2016;39:192–8.CrossRefPubMed
7.
Chen LN, Spivack J, Cao T, Saqi A, Benvenuto LJ, Bulman WA, et al. Characteristics and outcomes of lung cancer in solid organ transplant recipients. Lung Cancer. 2020;146:297–302.CrossRefPubMed
8.
Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant. 2013;13:214–21.CrossRefPubMed
9.
Zhang SX, Liu Y. Primary lung cancer in Chinese renal transplant recipients: a single-center analysis. Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:715–20.PubMed
10.
Drevet G, Duruisseaux M, Maury JM, Riche B, Grima R, Ginoux M, et al. Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience. Lung Cancer. 2020;139:55–9.CrossRefPubMed
11.
Kadomatsu Y, Tsubouchi H, Nakanishi K, Sugiyama T, Ueno H, Goto M, et al. Differential impacts of postoperative complications on patients’ survival in completely resected non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2021;69:1283–90.CrossRefPubMed
12.
Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547–61.CrossRefPubMed
13.
Maeda H, Kanzaki M, Sakamoto K, Kikkawa T, Isaka T, Oyama K, et al. Video-assisted thoracoscopic surgery after renal transplantation: a single-institution experience. Asian J Endosc Surg. 2016;9:37–43.CrossRefPubMed
14.
Yoshino I, Moriya Y, Suzuki K, Wakabayashi M, Saji H, Aokage K, et al. Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections. J Thorac Cardiovasc Surg. 2023;166:1222–31.CrossRefPubMed
15.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399:1607–17.CrossRefPubMed
16.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344–57.CrossRefPubMed
17.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711–23.CrossRefPubMed
18.
Dharia A, Boulet J, Sridhar VS, Kitchlu A. Cancer screening in solid organ transplant recipients: a focus on screening liver, lung, and kidney recipients for cancers related to the transplanted organ. Transplantation. 2022;106:e64–5.CrossRefPubMed
19.
20.
Rousseau-Gazaniol C, Fraboulet S, Couderc LJ, Kreis H, Borie R, Tricot L, et al. Lung cancer in renal transplant recipients: a case-control study. Lung Cancer. 2017;111:96–100.CrossRefPubMed
21.
Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008;8:2205–11.CrossRefPubMed
22.
Tsai HI, Lee CW, Kuo CF, See LC, Liu FC, Chiou MJ, et al. De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study. Oncotarget. 2017;8:36685–95.CrossRefPubMed
23.
Metadata
Title
Lung cancer after kidney transplantation: a 50-year experience at a single institution
Authors
Hiroki Watanabe
Yuka Kadomatsu
Shuhei Hakiri
Hiromu Yoshioka
Takahisa Hiramitsu
Kenta Futamura
Manabu Okada
Norihiko Goto
Shunji Narumi
Yoshihiko Watarai
Toyofumi Fengshi Chen-Yoshikawa
Publication date
28-03-2024
Publisher
Springer Nature Singapore
Published in
Surgery Today
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-024-02819-9